Results 71 to 80 of about 15,205 (209)

A real-world pharmacovigilance analysis of potential ototoxicity associated with sacubitril/valsartan based on FDA Adverse Event Reporting System (FAERS)

Scientific Reports
Sacubitril/valsartan, a first-in-class angiotensin receptor neprilysin inhibitor, is widely used to treat heart failure. Despite its efficacy, sacubitril/valsartan inevitably causes adverse events such as hypotension, renal dysfunction, hyperkalemia, and
Ning Wang, Haijun Wang, Ying Chen, Yanfeng Wang   +3 more
doaj   +1 more source

Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study

Indian Heart Journal, 2020
Objectives: To determine efficacy and safety of sacubitril/valsartan compared with enalapril in Indian patients of PARADIGM-HF trial. Methods: A randomized, double-blind, active-controlled, phase III sub-study (NCT01035255) was conducted between April ...
Anil Ranjeetmal Jain, Rakesh Kumar Aggarwal, Nanyam Srinivas Rao, Gauri Billa, Shankar Kumar   +4 more
doaj   +1 more source

Efficacy and safety of sacubitril/valsartan on heart failure with preserved ejection fraction: A meta-analysis of randomized controlled trials

Frontiers in Cardiovascular Medicine, 2022
AimsThe efficacy and safety of sacubitril/valsartan for patients with heart failure with preserved ejection fraction (HFpEF) are controversial. Hence, the primary objective of the study was to evaluate the efficacy and safety of sacubitril/valsartan ...
Wanqian Yu, Hongzhou Zhang, Wen Shen, Fan Luo, Shuai Yang, Lujin Gan, Yuanbin Zhao, Pingping Yang, Qinghua Wu   +8 more
doaj   +1 more source

Role of Echocardiography in Evaluation of the Effects of Sacubitril–Valsartan on Vascular Stiffness in Patients with Heart Failure: Review Article [PDF]

, 2022
Elshaimaa Ali Elsadek Seaoud, Tarek Ahmad Naguib, Ismail Talha Elbarky, Moataz Abdelmonem Elkot   +3 more
openalex   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Sacubitril/valsartan: research progress of multi-channel therapy for cardiorenal syndrome

Frontiers in Pharmacology, 2023
Cardiorenal syndrome (CRS) results from complex interaction between heart and kidneys, inducing simultaneous acute or chronic dysfunction of these organs.
Shuangcui Wang, Yuli Wang, Yun Deng, Jiaqi Zhang, Xijuan Jiang, Jianchun Yu, Jiali Gan, Wenyun Zeng, Maojuan Guo   +8 more
doaj   +1 more source

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Efficacy and safety of sacubitril‐valsartan in heart failure: a meta‐analysis of randomized controlled trials

ESC Heart Failure, 2020
Aims Sacubitril‐valsartan has been shown to have superior effects over angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers in patients with heart failure (HF) and hypertension.
Hongzhou Zhang, Tieqiu Huang, Wen Shen, Xiuxiu Xu, Pingping Yang, Dan Zhu, Haiyang Fang, Hongbing Wan, Tao Wu, Yanqing Wu, Qinghua Wu   +10 more
doaj   +1 more source

Hyperkalemia and Renin-Angiotensin-Aldosterone System Inhibitors Dose Therapy in Heart Failure With Reduced Ejection Fraction. [PDF]

, 2019
Renin-angiotensin-aldosterone system inhibitors (RAASi) are known to improve outcomes in patients who have heart failure with reduced ejection fraction (HFrEF).
Agewall, S, Rosano, GM, Spoletini, I, Vitale, C   +3 more
core   +2 more sources

Adverse events with sacubitril/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system [PDF]

, 2021
open5noThe author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: D, ER and FDP are supported by institutional funds from Ricerca Fondamentale Orientata.Aims: The aim of this study

core   +1 more source